Prometheus: Bound For Clarification Or Confusion?

Law360, New York (July 13, 2011, 1:23 PM EDT) -- On June 20, 2011, the U.S. Supreme Court granted certiorari for the second time in Prometheus Labs. Inc. v. Mayo Collaborative Servs., after having already granted certiorari last year, vacating and remanding to the Federal Circuit for further consideration in light of Bilski. The patent claims at issue in Prometheus are medical method claims directed at administering a drug to treat autoimmune disorders, and determining whether the metabolite level of the drug falls within a range correlated with efficacy but not toxicity.

One could speculate as...
To view the full article, register now.